Skip to main content
SpringerLink
Log in

Radioimmunotherapy

Potential as a Therapeutic Strategy in Non-Hodgkin’s Lymphoma

  • Leading Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Lymphomas are the fifth most common malignancy in the United States and are increasing in incidence. Despite being among the most responsive malignancies to radiation and chemotherapy, the majority of patients relapse or have progressive disease. Monoclonal antibodies (MAbs) directed at cell-specific surface antigens have been useful in the diagnosis of lymphomas and, more recently, the therapeutic mouse-human chimeric MAb rituximab has demonstrated effectiveness in B cell lymphomas. Conjugating MAbs to radionuclides is a strategy for improving the efficacy of MAb lymphoma therapy by delivering radiation in close proximity to the tumour (radioimmunotherapy or RIT). In addition, the low dose rate of the delivered radiation may exert a greater antitumour activity than an equivalent dose of conventional external beam radiation. The antigenic targets for MAb therapy have included CD20, CD22, HLA-DR, and B cell idiotype. Radionuclides that have been used include iodine-131, yttrium-90, and copper-67; there are relative merits and disadvantages to each source of radiation. Clinical studies to date have focused on relapsed and refractory patients with both indolent and aggressive lymphomas, although more recent studies have included previously untreated patients with indolent lymphoma. Radioimmunoconjugate has been delivered as either single or multiple doses. Response rates have varied widely, dependent on the patient population and the response criteria. Of note, complete responses can be achieved in this typically refractory patient group. Toxicities have generally consisted of mild infusion-related nausea, fever, chills, and asthenia. Neutropenia and thrombocytopenia are the dose-limiting toxicities and have prompted the incorporation of autologous stem cell support as a means of achieving dose escalation. To date, RIT has been delivered to highly selected patients in relatively few centres with requisite equipment and specialised personnel. In addition to these requirements, cost is likely to be a barrier to widespread use. The combination of RIT with chemotherapy at conventional or high dose, or with biological agents is a fertile area for investigation. The potential of RIT in the treatment for lymphomas will be defined only by well designed comparative prospective clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–95

    PubMed  CAS  Google Scholar 

  2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7

    Article  PubMed  Google Scholar 

  3. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40: 3147–54

    PubMed  CAS  Google Scholar 

  4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33

    PubMed  CAS  Google Scholar 

  5. Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic sarcoma antibodies. Cancer 1953; 6:619–23

    Article  PubMed  CAS  Google Scholar 

  6. Illidge TM, Cragg MS, McBride HM, et al. The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma. Blood 1999; 94: 233–43

    PubMed  CAS  Google Scholar 

  7. Tutt AL, French RR, Illidge TM, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol 1998; 161: 3176–85

    PubMed  CAS  Google Scholar 

  8. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996; 14: 1383–400

    PubMed  CAS  Google Scholar 

  9. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 2188–95

    PubMed  CAS  Google Scholar 

  10. McLaughlin P, White CA, Grillo-Lopez AJ, et al. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Huntingt) 1998; 12: 1763–9

    CAS  Google Scholar 

  11. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–32

    PubMed  CAS  Google Scholar 

  12. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 1998; 16: 3246–56

    PubMed  CAS  Google Scholar 

  13. Tuscano JM, Riva A, Toscano SN, et al. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 1999; 94: 1382–92

    PubMed  CAS  Google Scholar 

  14. Sato S, Tuscano JM, Inaoki M, et al. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 1998; 10: 287–97

    Article  PubMed  CAS  Google Scholar 

  15. Leonard JP, Coleman M, Schuster MW, et al. Immunotherapy of NHL with epratuzumab (anti-CD22 monoclonal antibody): excellent tolerability with objective responses. Proc ASCO 2000; 19: 17a

    Google Scholar 

  16. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376–88

    PubMed  CAS  Google Scholar 

  17. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999; 26: 52–7

    PubMed  CAS  Google Scholar 

  18. Verhey LJ. Principles of radiation physics. In: Leibel SA, Phillips TL, editors Textbook of radiation oncology. Philadelphia: W.B. Saunders Company; 1998: 91–114

    Google Scholar 

  19. Moi MK, DeNardo SJ, Meares CF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res 1990; 50:789s–93s

    PubMed  CAS  Google Scholar 

  20. Esteban JM, Schlom J, Gansow OA, et al. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1987; 28: 861–70

    PubMed  CAS  Google Scholar 

  21. O’Donnell RT, DeNardo SJ, DeNardo GL, et al. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate 2000; 44: 187–92

    Article  PubMed  Google Scholar 

  22. Kosmas C, Snook D, Gooden CS, et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992; 52: 904–11

    PubMed  CAS  Google Scholar 

  23. Knox SJ, Levy R, Miller RA, et al. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 1990; 50: 4935–40

    PubMed  CAS  Google Scholar 

  24. DeNardo SJ, DeNardo GL, O’Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 1987; 2: 49–53

    PubMed  CAS  Google Scholar 

  25. DeNardo GL, DeNardo SJ, Lamborn KR, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-l antibody. Cancer Biother Radiopharm 1998; 13: 239–54

    Article  PubMed  CAS  Google Scholar 

  26. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience [in process citation]. Blood 2000; 96: 1259–66

    PubMed  CAS  Google Scholar 

  27. Buchsbaum DJ, Wahl RL, Nonnolle DP, et al. Therapy with unlabeled and I-131 labeled pan B-cell monoclonal antibodies in nude mice bearing Raji Burkitt lymphoma xenografts. Cancer Res 1992; 52: 6476–81

    PubMed  CAS  Google Scholar 

  28. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–52

    PubMed  CAS  Google Scholar 

  29. Press OW. Prospects for the management of non-Hodgkin’s lymphomas with monoclonal antibodies and immunoconjugates. Cancer J Sci Am 1998; 4Suppl. 2: S19–S26

    PubMed  Google Scholar 

  30. Kaminski MS, Estes J, Regan D, et al. Front-line therapy of advanced B cell low-grade lymphoma (LGL) with radiolabeled anti-B1 antibody: initial experience. Proc ASCO 1997; 16: 15a

    Google Scholar 

  31. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17: 3793–803

    PubMed  CAS  Google Scholar 

  32. White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 1996; 87: 3640–9

    PubMed  CAS  Google Scholar 

  33. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue [abstract]. J Clin Oncol 1998; 16: 3270–8

    PubMed  CAS  Google Scholar 

  34. Dewey WC, Bedford JS. Radiobiologic principles. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. Philadelphia: W.B. Saunders Company; 1998: 3–24

    Google Scholar 

  35. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 5th ed. Philadelphia-New York: Lippincott-Raven; 1997: 467–83

    Google Scholar 

  36. Witzig TE, White CA, Gordon LI, et al. Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-Cell NHL. Blood 2000; 96(11): 831

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, UC Davis School of Medicine, Sacramento, California, USA

    Ted Wun, David S. Kwon & Joseph M. Tuscano

  2. Section of Hematology Oncology, VA Northern California Healthcare System, Martinez, California, USA

    Ted Wun & Joseph M. Tuscano

Authors
  1. Ted Wun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David S. Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph M. Tuscano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ted Wun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wun, T., Kwon, D.S. & Tuscano, J.M. Radioimmunotherapy. BioDrugs 15, 151–162 (2001). https://doi.org/10.2165/00063030-200115030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115030-00002

Keywords

Search

Navigation